Abstract

ObjectiveTo review the efficacy and safety of low-dose versus standard-dose enzalutamide, apalutamide or darolutamide treatment for metastatic prostate cancer.Methods and analysisKeyword searches in MEDLINE and EMBASE up to 1 June...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents
Johann De Bono ... Susan Masson
Cancer Treatment Reviews | VOL. 40
Johann De Bono, et. al.Johann De Bono ... Susan Masson
16 Aug 2013
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
Conrad Lee ... Kuen Chan
Clinical genitourinary cancer | VOL. 16
Conrad Lee, et. al.Conrad Lee ... Kuen Chan
21 Jul 2018
Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients
A Thomas ... M Zerbib
European Journal of Cancer | VOL. 72
A Thomas, et. al.A Thomas ... M Zerbib
24 Dec 2016
Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience.
Irshad Ismail ... Praveen Kumar Shenoy Vp
Ecancermedicalscience | VOL. 17
Irshad Ismail, et. al.Irshad Ismail ... Praveen Kumar Shenoy Vp
14 Aug 2023
View more papers

More From: BMJ Oncology

Paper Title
Journal
Date
Author
Patterns of cytotoxic T-cell densities in immunogenic endometrial cancers reveal a potential mechanism for differences in immunotherapy efficacy
Neil Ryan ... Emma Crosbie
BMJ Oncology | VOL. 3
Neil Ryan, et. al.Neil Ryan ... Emma Crosbie
21 May 2024
Careful take-off by the EQ-5D-5L tool in lung cancer: fly little one, fly!
Kurt G Tournoy
BMJ Oncology | VOL. 3
Kurt G TournoyKurt G Tournoy
15 May 2024
Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy
Kuan Liao ... Sabine N Van Der Veer
BMJ Oncology | VOL. 3
Kuan Liao, et. al.Kuan Liao ... Sabine N Van Der Veer
15 May 2024
Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa
Dorothy Chilambe Lombe ... Susan Msadabwe
BMJ Oncology | VOL. 3
Dorothy Chilambe Lombe, et. al.Dorothy Chilambe Lombe ... Susan Msadabwe
01 May 2024
View more papers